Agricultural Innovation marketplace-South-south cooperation beyond theory

Agricultural Innovation Marketplace - South - South Cooperation Beyond Theory provides a thorough discussion of the creation , the current status , and future of the Agriculture Innovation Marketplace ( The MKTPlace ) , an international , open partnership aiming to contribute to agricultural development in Africa , Latin America , and the Caribbean . Using the recent success of Brazilian agriculture , this partnership seeks to learn from those achievements , financing and organizing projects in other developing countries . Beginning with a brief outline of Brazil's development , this book focuses on the MKTPlace as an international partnership that supports , through policy dialogues , knowledge sharing and agricultural research , smallholder development in Africa , Latin America and the Caribbean , with the final goal of reducing hunger and poverty , and creating growth

Differences in Blood and Milk Fatty Acid Profile of Primiparous and Multiparous Mediterranean Buffaloes Cows During Transition Period and Early Lactation

The objective of this study was to determine the differences in blood and fatty acid (FA) profile between primiparous and multiparous Mediterranean buffaloes cows from 28 days of expected calving date until 56 days in milk. Nine multiparous (MUL) and 7 primiparous (PRI) cows were used in the present study, animals grazed in Brachiaria decumbens and supplemented with 2.0 kg of concentrate/day. Blood and milk samples were collected once a week and data were submitted to repeated measures analysis using PROC MIXED of SAS. Multiparous cows presented higher concentrations of glucose and non-esterified FA during pre- and post-partum period, higher cholesterol during post-partum when compared to PRI. Milk yield and fat content were higher for MUL (6.44 kg/d and 7.89%) when compared to PRI (5.66 kg/d and 6.75%). Palmitic and palmitoleic FA were lower and C18:0, C18:1 trans-11 and C18:1 cis-9 FAwere higher in MUL cows. Multiparous buffalo cows demonstrated higher milk yield and fat content than PRI, and milk FA profile of MUL had higher amounts of C18:0 FA. Multiparous buffalos presented higher non-esterified fatty acid, which altered milk fat content, and higher milk yield than primiparous cows. Furthermore, multiparous cows presented a higher content of FA from incomplete biohydrogenation process

Evaluation of the Milk Fatty Acid Profile from Mediterranean Buffalo Cows in the First Eight Weeks of Lactation

The aim of this study was to evaluate the fatty acid composition of buffalo milk in the first eight weeks oflactation. It was used 18 cows multiparous Buffaloes of Mediterranean race, the data collection starting four weeksbefore of the calving provided by the 8th week of lactation. The animals were mechanically milked once daily in themorning. The milk samples used for composition analysis were collected weekly from parturition to eight weeks oflactation. There was effect of weeks during the transition period and early lactation for fat yield (kg/day) and for bodyweight of the buffalo cows in lactation (kg).There was effect of weeks of lactation on the fatty acid composition of milkfat.Variations in levels of unsaturated fatty acids of milk fat of buffaloes are similar to those found in dairy cows of thepartum to eighth week of lactation

Complex B Vitamin Improves Performance of Mediterranean Buffalo Calves in Artificial Suckling from Birth to Weaning

The aim of this study was to evaluate the ponderal development, blood parameters and hematological from buffalo calves in artificial suckling supplemented with vitamin-mineral additive from birth to weaning. 18 buffalo calves were used and divided into two random groups: 1) control group; 2) group supplemented with vitamin B complex (Metacell ®). To evaluation of the ponderal development, the calves were weighed weekly and measured the thoracic perimeter, height and body length. Blood samples were collected weekly throughout the experimental period by jugular vein puncture. The group of calves supplemented with additives showed the greatest ponderal development in relation to the control group. Similarly the group of calves supplemented with additive has higher concentration of total cholesterol, urea and total protein. However there was no additive effect on the levels of glucose, albumin and beta-hydroxybutyrate. The values of leukocytes, neutrophils, eosinophils, lymphocytes increased with the oral use of the additive in relation to the control group. This study supports the definition of reference values for the evaluation of buffalo calves during suckling period. The additive use to buffalo calves improves ponderal performance without significantly alter the metabolic profile

Biochemical Characterization of an In-House Coccidioides Antigen: Perspectives for the Immunodiagnosis of Coccidioidomycosis

The objective of this study was to evaluate the reactivity of an in-house antigen, extracted from a strain of C. posadasii isolated in northeastern Brazil, by radial immunodiffusion and Western blotting, as well as to establish its biochemical characterization. the protein antigen was initially extracted with the use of solid ammonium sulfate and characterized by 1-D electrophoresis. Subsequently, it was tested by means of double radial immunodiffusion and Western blotting. A positive reaction was observed against the antigen by both immunodiagnostic techniques tested on sera from patients suffering from coccidioidomycosis. Besides this, two immunoreactive protein bands were observed and were revealed to be a beta-glucosidase and a glutamine synthetase after sequencing of the respective N-terminal regions. Our in-house Coccidioides antigen can be promising as a quick and low-cost diagnostic tool without the risk of direct manipulation of the microorganism.Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Coordination for the Improvement of Higher Education PersonnelUniv Fed Ceara, Specialized Med Mycol Ctr, Sch Med, BR-60430270 Fortaleza, Ceara, BrazilUniv Estadual Ceara, Postgrad Program Vet Sci, Sch Vet Med, BR-60740000 Fortaleza, Ceara, BrazilUniv Fed Ceara, Dept Biochem & Mol Biol, BR-60455760 Fortaleza, Ceara, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, BR-04021001 São Paulo, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, BR-04021001 São Paulo, BrazilCNPq: 302574/2009-3CNPq: 306637/2010-3Coordination for the Improvement of Higher Education Personnel: CAPES/PNPD2103/2009Web of Scienc

Assessment of genetically modified maize DP4114 × MON 89034 × MON 87411 × DAS‐40278‐9 and subcombinations, for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA GMO‐NL‐2020‐171)

Genetically modified maize DP4114 × MON 89034 × MON 87411 × DAS-40278-9 was developed by crossing to combine four single events: DP4114, MON 89034, MON 87411 and DAS-40278-9. The GMO Panel previously assessed the four single maize events and two of the subcombinations and did not identify safety concerns. No new data on the single maize events or the assessed subcombinations were identified that could lead to modification of the original conclusions on their safety. The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate that the combination of the single maize events and of the newly expressed proteins in the four-event stack maize does not give rise to food and feed safety and nutritional concerns. Therefore, no post-market monitoring of food/feed is considered necessary. In the case of accidental release of viable four-event stack maize grains into the environment, this would not raise environmental safety concerns. The GMO Panel assessed the likelihood of interactions among the single events in eight of the maize subcombinations not previously assessed and concludes that these are expected to be as safe as the single events, the previously assessed subcombinations and the four-event stack maize. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of maize DP4114 × MON 89034 × MON 87411 × DAS-40278-9. Post-market monitoring of food/feed is not considered necessary. The GMO Panel concludes that the four-event stack maize and its subcombinations are as safe as its non-GM comparator and the tested non-GM maize varieties with respect to potential effects on human and animal health and the environment

Assessment of genetically modified maize MON 95379 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2020‐170)

Genetically modified maize MON 95379 was developed to confer insect protection against certain lepidopteran species. These properties were achieved by introducing the cry1B.868 and cry1Da_7 expression cassettes. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between maize MON 95379 and its conventional counterpart needs further assessment. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the Cry1B.868 and Cry1Da_7 proteins as expressed in maize MON 95379. The GMO Panel finds no evidence that the genetic modification impacts the overall safety of maize MON 95379. In the context of this application, the consumption of food and feed from maize MON 95379 does not represent a nutritional concern in humans and animals. Therefore, no post-market monitoring of food/feed is considered necessary. In the case of accidental release of viable maize MON 95379 grains into the environment, this would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of maize MON 95379. The GMO Panel concludes that maize MON 95379 is as safe as its conventional counterpart and the tested non-GM maize varieties with respect to potential effects on human and animal health and the environment

Assessment of genetically modified Maize MON 87429 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2019‐161)

Maize MON 87429 was developed to confer tolerance to dicamba, glufosinate, quizalofop and 2,4-D herbicides. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between maize MON 87429 and its conventional counterpart needs further assessment, except for the levels of phytic acid in grains, which do not raise nutritional and safety concerns. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the DMO, PAT, FT_T and CP4 EPSPS proteins as expressed in maize MON 87429. The GMO Panel finds no evidence that the genetic modification impacts the overall safety of maize MON 87429. In the context of this application, the consumption of food and feed from maize MON 87429 does not represent a nutritional concern in humans and animals. The GMO Panel concludes that maize MON 87429 is as safe as the conventional counterpart and non-GM maize reference varieties tested, and no post-market monitoring of food/feed is considered necessary. In the case of accidental release of viable maize MON 87429 grains into the environment, this would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of maize MON 87429. The GMO Panel concludes that maize MON 87429, as described in this application, is as safe as its conventional counterpart and the tested non-GM maize reference varieties with respect to potential effects on human and animal health and the environment

Assessment of genetically modified maize MON 87419 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2017‐140)

Genetically modified maize MON 87419 was developed to confer tolerance to dicamba- and glufosinate-based herbicides. These properties were achieved by introducing the dmo and pat expression cassettes. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between maize MON 87419 and its conventional counterpart needed further assessment, except for the levels of arginine and protein in grains which did not raise safety and nutritional concerns. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the dicamba mono-oxygenase (DMO) and phosphinothricin N-acetyltransferase (PAT) proteins as expressed in maize MON 87419. The GMO Panel finds no evidence that the genetic modification impacts the overall safety of maize MON 87419. In the context of this application, the consumption of food and feed from maize MON 87419 does not represent a nutritional concern in humans and animals. The GMO Panel concludes that maize MON 87419 is as safe as the conventional counterpart and non-GM maize varieties tested, and no post-market monitoring of food/feed is considered necessary. In the case of accidental release of viable maize MON 87419 grains into the environment, this would not raise environmental safety concerns. The postmarket environmental monitoring plan and reporting intervals are in line with the intended uses of maize MON 87419. The GMO Panel concludes that maize MON 87419 is as safe as its conventional counterpart and the tested non-GM maize varieties with respect to potential effects on human and animal health and the environment

Assessment of genetically modified maize GA21 × T25 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐DE‐2016‐137)

Genetically modified maize GA21 x T25 was developed by crossing to combine two single events: GA21 and T25. The GMO Panel previously assessed the two single maize events and did not identify safety concerns. No new data on the single maize events were identified that could lead to modification of the original conclusions on their safety. The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate that the combination of the single maize events and of the newly expressed proteins in maize GA21 x T25 does not give rise to food and feed safety and nutritional concerns. The GMO Panel concludes that maize GA21 x T25, as described in this application, is as safe as its conventional counterpart and the non-GM reference varieties tested, and no post-market monitoring of food and feed is considered necessary. In the case of accidental release of viable maize GA21 x T25 grains into the environment, this would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of maize GA21 x T25. Post-market monitoring of food and feed is not considered necessary. The GMO Panel concludes that maize GA21 x T25 is as safe as its conventional counterpart and the non-GM reference varieties tested, with respect to potential effects on human and animal health and the environment